United States
Securities and Exchange Commission
Washington, D. C. 20549
FORM 10-Q/A
(Amendment No. 1)
| [X] | QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2012
| [ ] | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from _____ to _____
Commission File No. 1-32674
AOXING PHARMACEUTICAL COMPANY, INC.
(Exact Name of Registrant as Specified in its Charter)
| Florida | 65-0636168 |
| (State or other jurisdiction | (I.R.S. Employer ID Number) |
| of incorporation or organization) | |
444 Washington Blvd, Suite 3338, Jersey City, NJ 07310
(Address of Principal Executive Offices)
Issuer's Telephone Number: (646) 367-1747
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No ___
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.) Yes X No ____
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One)
Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company X
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No X
APPLICABLE ONLY TO CORPORATE ISSUERS: Indicate the number of shares outstanding of each of the Registrant's classes of common stock, as of the latest practicable date:
As of November 14, 2012 the number of shares outstanding of the Registrant’s common stock was 49,694,822 with $.001 par value.
Amendment No. 1: Explanatory Note
This amendment is being filed in order to file the interactive data files.
PART II - OTHER INFORMATION
Item 6. Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
| | AOXING PHARMACEUTICAL COMPANY, INC. |
| Date: November 30, 2012 | By: /s/ Zhenjiang Yue |
| | Zhenjiang Yue, Chief Executive Officer |
| | (Principal Executive Officer) |
| Date: November 30, 2012 | By: /s/ Guoan Zhang |
| | Guoan Zhang, Acting Chief Financial Officer |
| | (Principal Accounting and Financial Officer) |
